Current concepts about testicular cancer

European Journal of Surgical Oncology

Volumn 23, Issue 4, 1997, Pages 354-360

  Van Basten, J P ^a   Schraffordt Koops, H ^a   Sleijfer, D Th ^a   Pras, E ^a   Van Driel, M F ^a   Hoekstra, H J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Review; Testicular cancer; Toxicity; Treatment

Indexed keywords

BLEOMYCIN; CISPLATIN; ETOPOSIDE; TUMOR MARKER; VINBLASTINE;

ADULT; ATHEROSCLEROSIS; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; DISEASE MANAGEMENT; EJACULATION; ENDOCRINE DISEASE; GERM CELL; HISTOPATHOLOGY; HUMAN; HYPERLIPIDEMIA; LEYDIG CELL; LYMPH NODE DISSECTION; MALE; MALE INFERTILITY; MALE SEXUAL DYSFUNCTION; MEDICAL LITERATURE; MINIMAL RESIDUAL DISEASE; MORBIDITY; NEPHROTOXICITY; PARESTHESIA; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RAYNAUD PHENOMENON; REVIEW; SEMINOMA; SEXUAL FUNCTION; TESTIS CANCER; TESTIS DISEASE; WELLBEING;

EID: 0030880517     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0748-7983(97)90966-5     Document Type: Article

References (96)

1. Visser O, Coebergh JWW, Scheuten LJ (eds). Coordinating Council of Comprehensive Cancer Centres. In: Incidence of cancer in The Netherlands 1992. 4th Report of The Netherlands Cancer Registry. Utrecht, 1995: 56-7.
2. Adami HO, Bergstrom R, Mohner M, et al. Testicular cancer in nine northern European countries. Int J Cancer 1994; 59: 33-8.
3. Hoff Wanderas E, Tretli S, Fossa SD. Trends in incidence of testicular cancer in Norway. Eur J Cancer 1995; 31 A: 2044-8.
4. Harding M, Hole D, Gillis C. The epidemiology of nonseminomatous germ-cell tumours in the west of Scotland 1975-1989. Br J Cancer 1995; 72: 1559-62.
5. Raina V, Shukla NK, Gutpa NP, Deo S, Rath GK. Germ cell tumours in uncorrected cryptorchid testis at Institute Rotary Cancer Hospital, New Delhi. Br J Cancer 1995; 71: 380-2.
6. Zimmerman RR, Kung'u A. Testicular neoplasms in Kenyan Africans. Cancer 1978; 41: 2452-5.
7. Feuer EJ. Incidence of testicular cancer in U.S. men. J Natl Cancer Inst 1995; 6: 405-6.
8. Eeden SK van den, Weiss NS. Is testicular cancer in blacks increasing? Am J Public Health 1989; 79: 1553-4.
9. United Kingdom Testicular Cancer Study Group. Aetiology of testicular cancer: association with congenital abnormalities, age at puberty, infertility and exercise. Br Med J 1994; 308: 1393-9.
10. Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Strom BL, Harlap S, Shapiro S. The relation of vasectomy to the risk of testicular cancer. Am J Epidemiol 1994; 140: 431-8.
11. Boyle P, Zaridze DG. Risk factors for prostate and testicular cancer. Eur J Cancer 1993; 29A: 1048-55.
12. Forman D, Gallagher R, Möller H, Swerdlow TJ. Aetiology and epidemiology of testicular cancer: report of consensus group. Prog Clin Biol Res 1990; 357: 245-53.
13. Giwercman A, Grindsted J, Hansen B, Jensen OM, Skakkebaek NE. Testicular cancer risk in boys with maldescended testis: a cohort study. J Urol 1987; 138: 1214-6.
14. Strader CH, Weiss NS, Daling JR, McKnight B. Cryptorchidism, orchidopexy, and risk for testicular cancer. Am J Epidemiol 1988; 127: 1013-8.
15. Pike MC, Chilvers C, Peckham MJ. Effect of age at orchidopexy on risk of testicular cancer. Lancet 1986; I: 1246-8.
16. Meyts R de, Skakkebaek NE. The possible role of sex hormones in the development of testicular cancer. Eur Urol 1993; 23: 54-61.
17. Kroman N, Frisch M, Westergaard T, Olsen JH, Melbye M. Estrogen related cancer risk in mothers of testicular cancer patients. Eur J Cancer 1995; 31A: 900 S187 (Abstract).
18. Henderson BE, Bernstein L, Ross RK, Depue RH, Judd HL, Pike MC. The early in-utero oestrogen and testosterone environment of black and whites: potential effects on male offspring. Br J Cancer 1988; 57: 216-8.
19. Walker AH, Bernstein L, Warren DW, Zheng X, Henderson BE. The effect of in utero ethinyl oestradiol exposure on the risk of cryptorchid testis and testicular teratoma in mice. Br J Cancer 1990; 62: 599-622.
20. Dieckman KP, Loy V, Büttner P. Prevalence of bilateral testicular germ cell tumours and early detection based on testicular intra-epithelial neoplasia. Br J Urol 1993; 71: 340-5.
21. Leeuwen FE van, Stiggelbout AM, Belt-Dusebout AW van den, Noyon R, Eliel MR, Kerkhoff EMM, Delemarre JFM, Somers R. Second cancer risk following testicular cancer: a follow-up of 1,909 patients. J Clin Oncol 1993; 11: 415-24.
22. Basten JP van, Hoekstra HJ, Driel MF van, Sleijfer DTh, Droste JHJ, Schraffordt Koops H. Cisplatin-based chemotherapy changes the incidence of bilateral testicular cancer. Ann Surg Oncol 1997; 4: 342-8.
23. Nicholson PW, Harland SJ. Inheritance and testicular cancer. Br Med J 1995; 71: 421-6.
24. Cooper MA, Fellows J, Einhorn LH. Familial occurrence of testicular cancer. J Urol 1994; 151: 1022-3.
25. Smith RC, Rukstalis DB. Frequent loss of heterozygosity at lip loci in testicular cancer. J Urol 1995; 153: 1684-7.
26. Echten J van, Oosterhuis JW, Looijenga LHJ, et al. No recurrent structural abnormalities apart from i(12p) in primary germ cell tumors of the adult testis. Genes Chromos Cancer 1995; 14: 133-44.
27. Hentrich MU, Brack NG, Schmid P, Schuster T, Clemm C, Hartenstein RC. Testicular germ cell tumors in patients with human immunodeficiency virus infection. Cancer 1996; 77: 2109-16.
28. Sheinfeld J. Nonseminomatous germ cell tumor of the testis: current concepts and controversies. Urology 1994; 44: 2-14.
29. Capelouto CC, Clark PE, Ransil BJ, Loughin KR. Review of scrotal violation in testicular cancer: is adjuvant local therapy necessary? J Urol 1995; 153: 981-5.
30. Gels ME, Hoekstra HJ, Sleijfer DTh, et al. Detection of recurrence in patients with clinical stage I nonseminomatous testicular germ cell tumors and consequences for further follow-up: a single-centre 10-year experience. J Clin Oncol 1995; 13: 1188-94.
31. Fung CY, Garnick MB. Clinical stage I carcinoma of the testis: a review. J Clin Oncol 1988; 6: 734-50.
32. Hoskin P, Dilly S, Easton D, Horwich A, Hendry WF, Peckham MJ. Prognostic factors in stage I nonseminomatous testicular tumours managed by orchidectomy and surveillance: implications for adjuvant chemotherapy. J Clin Oncol 1986; 4: 1031-6.
33. Klein EA. Tumor markers in testis cancer. Urol Clin North Am 1993; 20: 67-73.
34. Gels ME, Marrink J, Visser P, et al. The importance of a new tumor marker TRA-1-60 in the follow-up of patients with clinical stage 1 nonseminomatous testicular germ cell tumors (NSTGCT). Ann Surg Oncol 1997 (in press).
35. Mead GM. On behalf of the I.G.C.C.C.G. International consensus prognostic classification for metastatic germ cell tumours treated with platinum based chemotherapy: final report of the International Germ Cell Cancer Collaboration Group. Proc Am Soc Clin Oncol 1995; 14: 255 (Abstract).
36. Wobbes Th, Blom JMH, Oldhoff J, Schraffordt Koops H. Lymphangiography in the diagnosis of non-seminoma tumors of the testis. J Surg Oncol 1982; 19: 1-4.
37. Prenger K, Eysman L, Homan van der Heide JN, Oldhoff J, Sleijfer DTh, Schraffordt Koops H, Oosterhuis JW. Thoracotomy as a staging procedure after chemotherapy in the treatment of stage III nonseminomatous carcinoma of the testis. Ann Thoracic Surg 1984; 38: 444-6.
38. Gelderman WAH, Laan JG van der, Schraffordt Koops H, Sleijfer DTh, Hoekstra HJ, Oldhoff J. Evaluation of staging methods for retroperitoneal metastases in patients with nonseminomatous testicular tumours: CT, lymphangiography, and exploratory laparotomy. J Med Imag 1989; 3: 288-96.
39. Hogeboom WR, Hoekstra HJ, Mooyaart EL, Sleijfer DTh, Freling NJM, Willemse PHB, Schraffordt Koops H. The role of magnetic resonance imaging and computed tomography in the treatment evaluation of retroperitoneal lymph-node metastases of non-seminomatous testicular tumors. Eur J Radiol 1991; 13: 31-6.
40. Peckham MJ, Barrett A, Horwich A, Hendry WF. Orchidectomy alone for stage I testicular nonseminoma. A progress report on the Royal Marsden Hospital study. Br J Urol 1983; 55: 754-9.
41. Einhorn LH. Treatment of testicular cancer: a new and improved model. J Clin Oncol 1990; 8: 1777-81.
42. Mead G, Stenning SP, Cullen MH, Horwich A, Fossa SD, Kaye SB. Medical Research Council prospective study of surveillance for stage I testicular teratoma. J Clin Oncol 1992; 10: 1762-8.
43. Maase H von der, Specht L, Jacobsen GK, et al. Surveillance following orchidectomy for stage I seminoma of the testis. Eur J Cancer 1993; 29A: 1931-4.
44. Duchesne GM, Horwich A, Dearnaley DP, Nicholls J, Jay G, Peckham MJ, Hendry WF. Orchidectomy alone for stage I seminoma of the testis. Cancer 1990; 65: 1115-8.
45. Sharda NN, Kinsella TJ, Ritter MA. Adjuvant radiation versus observation: A cost analysis of alternate management schemes in early stage testicular seminoma. J Clin Oncol 1996; 14: 2933-9.
46. Williams SD, Birch R, Einhorn LH, Irwin L, Greco FA, Loehrer PJ. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin and either vinblastine or etoposide. New Engl J Med 1987; 316: 1435-40.
47. Stoter G, Kaye S, Jones W, et al. Cisplatin and VP-16 + /-bleomycin (BEP vs EP) in good risk patients with disseminated non-seminomatous testicular cancer: a randomized EORTC GU Group study. Proc Am Soc Clin Oncol 1987; 6: 110 (Abstract).
48. Lemmes NWM, Gels ME, Sleijfer DTh, et al. Complications of venous access ports in 132 patients with disseminated testicular cancer treated with polychemotherapy. J Clin Oncol 1996; 14: 2916-22.
49. Lampe H, Dearnaley DP, Price A, Mehta J, Powles R, Nicholls J, Horwich A. High dose carboplatin and etoposide for salvage chemotherapy of germ cell tumours. Eur J Cancer 1995; 31A: 717-23.
50. Nichols CR, Andersen J, Lazarus HM, et al. High dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: an Eastern Cooperative Oncology Protocol. J Clin Oncol 1992; 10: 558-63.
51. Mulder POM, Vries EGE de, Schraffordt Koops H, et al. Chemotherapy with maximally tolerable doses of VP 16-213 and cyclophosphamide followed by autologous bone marrow transplantation for the treatment of relapsed or refractory germ cell tumors. Eur J Cancer Clin Oncol 1988; 24: 675-9.
52. Bosl GJ. Prognostic factors for metastatic testicular germ cell tumours: the Memorial Sloan-Kettering Cancer Model. Eur Urol 1993; 23: 182-7.
53. Donohue JP, Thornhill JA, Foster RS, Rowland RG, Bihrle R. Retroperitoneal lymphadenectomy for clinical stage A testis cancer (1965 to 1989): modifications of technique and impact on ejaculation. J Urol 1993; 149: 237-43.
54. Richie JP. Clinical stage I testicular cancer: the role of modified retroperitoneal lymphadenectomy. J Urol 1990; 144: 1160-3.
55. Wobbes Th, Eibergen R, Oldhoff J, Schraffordt Koops H. Results of retroperitoneal lymph node dissection and postoperative adjuvant chemotherapy with dactinomycin in the treatment of retroperitoneal metastases of nonseminomatous testicular germ cell tumors. Cancer 1983; 51: 1076-9.
56. Donohue JP, Thornhill JA, Foster RS, Bihrle R, Randall G, Rowland G, Einhorn LH. The role of retroperitoneal lymphadenectomy in clinical stage B testis cancer: The Indiana University experience (1965 to 1989). J Urol 1995; 153: 85-9.
57. Aprikian AG, Herr HW, Bajorin DF, Bosl GJ. Resection of postchemotherapy residual masses and limited retroperitoneal lymphadenectomy in patients with metastatic testicular nonseminomatous germ cell tumors. Cancer 1994; 74: 1329-34.
58. Wood DP Jr, Herr HW, Heller G, et al. Distribution of retroperitoneal metastases after chemotherapy in patients with nonseminomatous germ cell tumors. J Urol 1992; 148: 1812-6.
59. Tekgul S, Özen HA, Celebi I, Ozgu I, Ergen A, Demircin M, Remzi D. Postchemotherapeutic surgery for metastatic germ cell tumors: results of extended primary chemotherapy and limited surgery. Urology 1994; 43: 349-54.
60. Gels ME, Nijboer AP, Hoekstra HJ, et al. Complications of post-chemotherapy resection of retroperitoneal residual tumour mass in patients with nonseminomatous testicular germ cell tumours. Br J Urol 1997; 79: 263-8.
61. Gerber GN, Bissada NK, Hulbert JC, Kavoussi LR, Moore RG, Kantoff PW, Rukstalis DR. Laparoscopic retroperitoneal lymphadenectomy: multi-institutional analysis. J Urol 1994; 152: 1188-92.
62. Klotz L. Laparoscopic retroperitoneal lymphadenectomy for high-risk stage I nonseminomatous germ cell tumor: report of four cases. Urology 1994; 43: 752-6.
63. Horwich A, Dearnaley DP. Treatment of seminoma. Semin Oocol 1992; 19: 171-80.
64. Thomas G. Management of metastatic seminoma; role of radiotherapy. In: Horwich A (ed.) London: Chapman and Hall, 1991, 117-28.
65. Gietema JA, Sleijfer DTh, Willemse PHB, et al. Long-term follow-up of cardiovascular risk factors in patients given chemotherapy for disseminated nonseminomatous testicular cancer. Ann Intern Med 1992; 116: 709-15.
66. Bokemeyer C, Berger CC, Kuczyk MA, Schmoll HJ. Evaluation of long-term toxicity after chemotherapy for testicular cancer. J Clin Oncol 1996; 14: 2923-32.
67. Osanto S, Bukman A, Hoek F van, Sterk PJ, Laat JA de, Hermans J. Long-term effects of chemotherapy in patients with testicular cancer. J Clin Oncol 1992; 10: 574-9.
68. Berger CC, Bokemeyer C, Schneider M, Kuczyk MA, Schmoll HJ. Secondary Raynaud's phenomenon and other late vascular complications following chemotherapy for testicular cancer. Eur J Cancer 1995; 31 A: 2229-38.
69. Fossa SD, Lehne G, Heimdal K, Theodorsen L. Clinical and biochemical long-term toxicity after postoperative cisplatin-based chemotherapy in patients with low-stage testicular cancer. Oncology 1995; 52: 300-5.
70. Berger CC, Bokemeyer C, Schuppert F, Schmoll HJ. Endocrinological late effects after chemotherapy for testicular cancer. Br J Cancer 1996; 73: 1108-14.
71. Doll DC, Yarbro JW. Vascular toxicity associated with antineoplastic agents. Semin Oncol 1992; 19: 580-96.
72. Gerl A. Vascular toxicity associated with chemotherapy for testicular cancer. Anticancer Drugs 1994; 5: 607-14.
73. Icli F, Karaoguz H, Dincol D, Demirkazik A, Gunel N, Karaoguz R, Uner A. Severe vascular toxicity associated with cisplatin-based chemotherapy. Cancer 1993; 72: 587-93.
74. Vogelzang N, Torkelsong J, Kennedy B. Hypomagnesia, renal dysfunction and Raynaud's phenomenon in patients treated with cisplatin, vinblastine and bleomycin. Cancer 1992; 56: 2765-70.
75. Hansen SW, Olsen N, Rossing N, Rorth M. Vascular toxicity and mechanism underlying Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin. Ann Oncol 1990; 1: 289-92.
76. Hansen SW, Helweg-Larsen S, Trojaborg W. Long-term neurotoxicity in patients treated with cisplatin, vinblastine, and bleomycin for metastatic germ cell cancer. J Clin Oncol 1989; 7: 1457-61.
77. Boyer M, Raghavan D. Toxicity of treatment of germ cell tumors. Semin Oncol 1992; 19: 128-42.
78. Hansen SW, Berthelsen JG, Maase H von der. Long-term fertility and Leydig cell function in patients treated for germ cell cancer with cisplatin, vinblastine, and bleomycin versus surveillance. J Clin Oncol 1990; 8: 1695-8.
79. Costabile RA. The effects of cancer and cancer therapy on male reproductive function. J Urol 1993; 149: 1327-30.
80. Fossa SD, Aass N, Kaalhus O. Is routine pre-treatment cryopreservation worthwhile in the management of patients with testicular cancer? Br J Urol 1989; 64: 524-9.
81. Kolk BM van der, Mulder NH, Mantingh A, et al. Children born after their fathers had been treated with chemotherapy for testicular cancer. Eur J Obstet Gynecol Reprod Biol 1990; 34: 167-70.
82. Baniel J, Foster RS, Rowland RG, Bihrle R, Donohue JP. Complications of postchemotherapy retroperitoneal lymph node dissection. J Urol 1995; 153: 976-80.
83. Plukker JTh, Schraffordt Koops H, Sleijfer DTh. Oosterhuis JW, Jagt E van de. Intestinal hemorrhages in patients with a nonseminomatous testicular tumour. Cancer 1991; 68: 2630-2.
84. Baniel J, Foster RS, Rowland RG, Bihrle R, Donohue JP. Management of chylous ascites after retroperitoneal lymph node dissection for testicular cancer. J Urol 1993; 150: 1422-6.
85. Donohue JP, Rowland RG. Complications of retroperitoneal lymph node dissection. J Urol 1981; 125: 338-40.
86. Coogan CL, Hejase MJ, Wahle GR, Foster RS. Rowland RG, Bihrle R, Donohue JP. Nerve sparing post-chemotherapy retroperitoneal lymph node dissection for advanced testicular cancer. J Urol 1996; 156: 1656-8.
87. Hobisch A, Colleselli K, Ennemoser O. Horninger W, Poisel S, Janetschek G, Bartsch G. Modified retroperitoneal lymphadenectomy for testicular tumor: anatomical approach, operative techniques and results. Eur Urol 1993; 23: 39-43.
88. Donohue JP, Foster RS, Rowland RG, Bihrle R, Jones J, Geier G. Nerve-sparing retroperitoneal lymphadenectomy for testis tumor with nerve sparing for ejaculation. J Urol 1988; 139: 1220-4.
89. Nijman JM, Schraffordt Koops H, Oldhoff J, Kremer J, Jager S. Sexual function after bilateral retroperitoneal lymph node dissection for nonseminomatous testicular cancer. Arch Androl 1987; 18: 255-67.
90. Dieckman KP, Huland H, Gross AJ. A test for the identification of relevant sympathetic nerve fibres during nerve sparing retroperitoneal lymphadenectomy. J Urol 1992; 148: 1450-2.
91. Gregory RW, Foster RS, Bihrle R, Rowland RG, Bennett RM, Donohue JP. Nerve-sparing retroperitoneal lymphadenectomy after primary chemotherapy for metastatic testicular carcinoma. J Urol 1995; 140: 428-32.
92. Solosna E, Iborra I, Ricos JV, Monros JL, Dumont R, Casanova J, Guillem V. Preservation of antegrade ejaculation in retroperitoneal lymphadenectomy due to residual masses after chemotherapy for testicular carcinoma. Eur Urol 1994; 25: 199-203.
93. Recker F, Goepel M, Otto T, et at. An intra-operative seminal and prostate emission test as a control for nerve-sparing procedures in primary and secondary retro-peritoneal lymphadenectomy. Br J Urol 1996; 77: 133-7.
94. Nijman JM, Schraffordt Koops H, Oldhoff J, Sleijfer DTh. Sexual function after surgery and combination chemotherapy in men with disseminated nonseminomatous testicular cancer. J Surg Oncol 1988; 38: 182-6.
95. Hamilton CR, Horwich A, Bliss JM, Peckham MJ. Gastrointestinal morbidity of adjuvant radiotherapy in stage I malignant teratoma of the testis. Radiother Oncol 1987; 10: 85-90.
96. Horwich A, Hendry WF. Testicular cancer: reducing the toxicity of treatment of germ cell tumours. Recent Adv Urol Androl 1995; 7: 215-29.